journal article·2023-04-25

Glutathione/Glucose-Depleting Nanoparticles with NO Generation for Ferroptosis/Starvation/NO-Induced Cancer Therapy

Xingyu Fan, Botao Chen, Hui Xu, Anqiang Pan, Shuquan Liang, Songwen Tan, Yongju He

Chemistry of Materials· Volume 35· Issue 8
Publisher page

Abstract

Depleting intracellular glutathione (GSH) has emerged as a potent strategy to combat cancer. However, the existing GSH-depleting agents are too toxic or ineffective and standalone GSH depletion fails to yield a satisfactory curative effect. Herein, we present an intelligent nanoparticle that possesses GSH depletion, glucose consumption accompanied with H 2 O 2 production, and NO generation properties for multimodal cancer therapy. The nanoparticle is constructed by synthesis of tetrasulfide bond-doped mesoporous silica nanoparticles followed by conjugating glucose oxidase (GOx) on the surface and loading l -arginine ( l -Arg) into the mesopores. In this nanoparticle, the doped tetrasulfide bonds can quickly deplete GSH, which increases the cellular reactive oxygen species concentration to induce ferroptosis and meanwhile triggers particle biodegradation to expose the loaded l -Arg. Moreover, the elevated H 2 O 2 level activates l -Arg to release NO for NO therapy. GOx consumes glucose to initiate starvation therapy and simultaneously produces a large amount of H 2 O 2 . Importantly, the produced H 2 O 2 can not only potentiate ferroptosis but also promote NO release to enhance NO therapy. Besides, NO could in turn improve the efficacy of starvation therapy by damaging the mitochondria to block energy supply. In vitro and in vivo studies demonstrate that the nanoparticles show a great synergistic effect of ferroptosis/starvation/NO therapy, which can significantly kill cancer cells and remarkably inhibit tumor growth without obvious side effects. Therefore, we think that the designed nanoparticles may provide a promising paradigm for synergistic cancer therapy and hold a prospect in clinical trials.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Sulfur Compounds in Biology · Cancer, Stress, Anesthesia, and Immune Response

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Materials Science and Engineering, Central South University, Changsha, Hunan 410083, China

Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital, the First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, China

Institute of Super-Microstructure and Ultrafast Process in Advanced Materials, School of Physics and Electronics, Central South University, Changsha, Hunan 410083, China

Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China

Funding

Central South University · Central University Basic Research Fund of China · National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1021/acsnano.1c0049810.1021/acsnano.1c00498 ↗
2. 10.1039/D0CS00718H10.1039/D0CS00718H ↗
3. 10.1002/adma.20190527110.1002/adma.201905271 ↗
4. 10.1021/acs.nanolett.0c0496710.1021/acs.nanolett.0c04967 ↗
5. 10.1021/acs.chemmater.0c0408010.1021/acs.chemmater.0c04080 ↗
6. 10.1021/acsnano.0c0549910.1021/acsnano.0c05499 ↗
7. 10.1021/acs.chemmater.2c0164810.1021/acs.chemmater.2c01648 ↗
8. 10.1002/adfm.20190795410.1002/adfm.201907954 ↗
9. 10.1021/acsami.1c1132710.1021/acsami.1c11327 ↗
10. 10.1002/smll.20210610010.1002/smll.202106100 ↗
11. 10.1126/sciadv.abc437310.1126/sciadv.abc4373 ↗
12. 10.1186/s13046-018-0909-x10.1186/s13046-018-0909-x ↗
13. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
14. 10.1002/anie.20220284310.1002/anie.202202843 ↗
15. 10.1021/acsnano.1c0677710.1021/acsnano.1c06777 ↗
16. 10.1021/acsnano.2c0322210.1021/acsnano.2c03222 ↗
17. 10.1021/acs.chemmater.2c0172610.1021/acs.chemmater.2c01726 ↗
18. 10.1021/acsnano.1c1023110.1021/acsnano.1c10231 ↗
19. 10.7150/thno.3941210.7150/thno.39412 ↗
20. 10.1021/acs.nanolett.9b0526510.1021/acs.nanolett.9b05265 ↗
21. 10.1002/adma.20200689210.1002/adma.202006892 ↗
22. 10.1021/acsnano.9b0495410.1021/acsnano.9b04954 ↗
23. 10.1021/acsnano.9b0512410.1021/acsnano.9b05124 ↗
24. 10.1016/j.biomaterials.2020.12038410.1016/j.biomaterials.2020.120384 ↗
25. 10.1021/acs.nanolett.9b0097510.1021/acs.nanolett.9b00975 ↗
26. 10.1016/j.actbio.2021.12.01210.1016/j.actbio.2021.12.012 ↗
27. 10.1002/smll.20200174710.1002/smll.202001747 ↗
28. 10.1016/j.biomaterials.2022.12185410.1016/j.biomaterials.2022.121854 ↗
29. 10.1016/j.actbio.2019.10.00210.1016/j.actbio.2019.10.002 ↗
30. 10.1016/j.actbio.2022.02.02910.1016/j.actbio.2022.02.029 ↗
31. 10.1021/acsnano.1c1142210.1021/acsnano.1c11422 ↗
32. 10.1021/acsami.0c0479110.1021/acsami.0c04791 ↗
33. 10.1016/j.biomaterials.2022.12144810.1016/j.biomaterials.2022.121448 ↗
34. 10.1016/j.redox.2022.10235010.1016/j.redox.2022.102350 ↗
35. 10.1021/acsami.1c1535810.1021/acsami.1c15358 ↗
36. 10.1016/j.biomaterials.2018.03.04610.1016/j.biomaterials.2018.03.046 ↗
37. 10.1039/C9NR00732F10.1039/C9NR00732F ↗
38. 10.1002/smll.20210773210.1002/smll.202107732 ↗
39. 10.1002/adma.20180196410.1002/adma.201801964 ↗
40. 10.1002/advs.20200252510.1002/advs.202002525 ↗
41. 10.1039/D0NR07484E10.1039/D0NR07484E ↗
42. 10.1016/j.actbio.2021.12.01210.1016/j.actbio.2021.12.012 ↗
43. 10.1016/j.biomaterials.2018.09.00410.1016/j.biomaterials.2018.09.004 ↗
44. 10.1016/j.cej.2020.12804910.1016/j.cej.2020.128049 ↗
45. 10.1016/j.jcis.2018.05.10410.1016/j.jcis.2018.05.104 ↗
46. 10.1039/D1BM01944A10.1039/D1BM01944A ↗
47. 10.1002/adhm.20210156310.1002/adhm.202101563 ↗